.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,863,331

« Back to Dashboard
Patent 7,863,331 protects ANTARA (MICRONIZED) and is included in one NDA. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has eighty patent family members in thirty-six countries.

Summary for Patent: 7,863,331

Title:Pharmaceutical composition containing fenofibrate and method for the preparation thereof
Abstract:Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions.
Inventor(s): Criere; Bruno (Gravigny, FR), Suplie; Pascal (Montaure, FR), Chenevier; Philippe (Montreal, CA), Oury; Pascal (Le Chesnay, FR), Rotenberg; Keith S. (Denville, NJ), Bobotas; George (Tarpon Springs, FL)
Assignee: Ethypharm (Saint Cloud, FR)
Application Number:10/677,861
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 29th percentile
Forward Citations: 3rd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lupin Atlantis
ANTARA (MICRONIZED)
fenofibrate
CAPSULE;ORAL021695-001Nov 30, 2004RXNo7,863,331► subscribe TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
Lupin Atlantis
ANTARA (MICRONIZED)
fenofibrate
CAPSULE;ORAL021695-001Nov 30, 2004RXNo7,863,331► subscribe TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
Lupin Atlantis
ANTARA (MICRONIZED)
fenofibrate
CAPSULE;ORAL021695-003Nov 30, 2004RXYes7,863,331► subscribe TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,863,331

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France99 08923Jul 09, 1999

Non-Orange Book Patents for Patent: 7,863,331

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,658,212Pharmaceutical composition containing fenofibrate and method for the preparation thereof► subscribe
7,101,574Pharmaceutical composition containing fenofibrate and the preparation method► subscribe
8,529,952Pharmaceutical composition containing fenofibrate and method for the preparation thereof► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,863,331

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand546692► subscribe
New Zealand516416► subscribe
Norway335933► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc